RegulatoryCompany release

FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children

Essential Pharma · Mon 16 Nov 2026

Renaissance Pharma, part of Essential Pharma, says the anti-GD2 antibody has received the US designation for first-line use alongside induction chemotherapy; it is not approved anywhere.

Renaissance Pharma, part of Essential Pharma, announced on 16 November 2026 that the US Food and Drug Administration has granted Breakthrough Therapy Designation to daretabart, an anti-GD2 antibody.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Essential Pharma ↗

Article written by VigiEye from the official source (Essential Pharma). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →